The global myocardial infarction market size was valued at around USD 1,817 million in 2021 and is anticipated to expand at a CAGR of 5.9% during the forecast period, 2022–2030. The growth of the market is attributed to increasing incidence of cardiovascular disease, obesity, and hypertension.
A myocardial infarction, sometimes known as a heart attack, is a life-threatening illness that occurs when one or more coronary arteries get blocked, preventing blood from reaching the heart muscle. Various deaths have been reported as a result of severe cardiac strokes or heart attacks. STEMI heart attacks, NSTEMI heart attacks, and silent heart attacks are the three types of myocardial infarction. Electrocardiography, CT scan, chest x-ray, echocardiography, blood test, and other diagnostic tests can be used to diagnose such disorders. Pharmaceuticals such as aspirin thrombolytics, antiplatelet agents, and other medicines, as well as surgical treatments such as angioplasty bypass surgery and heart transplant can be used to treat a heart attack. Left ventricular assist devices, pacemakers, and implanted cardioverter defibrillators are some of the devices used to treat myocardial infarction.
The COVID-19 pandemic and lockdown in several nations throughout the world has had an impact on enterprises in all sectors, including the private healthcare sector. Because of the rigorous lockdown in certain places, the pandemic has damaged the whole healthcare supply chain. COVID-19 pandemic, which began in 2020, affected global health-care delivery, including delays in cardiovascular disease detection and treatment. As a result, the global myocardial infarction market is likely to be constrained by the effect of the coronavirus pandemic throughout the forecast period.
Market Trends, Drivers, Restraints, and Opportunities
- Increasing intake of sugar and sugar-based food, which gives rise to coronary artery disease, is expected to drive the market.
- Lack of physical activities and faulty dietary habits are projected to propel the market during the forecast period.
- Stringent regulatory policies by governments are anticipated to hinder the market.
- High cost of clinical trials is expected to hamper the market in the coming years.
- Advancements in technology and increasing acceptance of new treatment technologies are projected to create lucrative opportunities for market players.
Scope of the Report
The report on the global myocardial infarction market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Myocardial Infarction Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2021
|
|
Historic Data
|
2019–2020
|
|
Forecast Period
|
2022–2030
|
|
Segmentation
|
Diagnosis (Echocardiogram, Electrocardiogram, and Blood Tests [Troponin and CK-MB]), Treatments (Drugs [Angiotensin-receptor Blockers, Analgesics, Thrombolytics, Antiplatelet Agents, Glycoprotein IIb/IIIa Inhibitors, Antithrombotic Agents, Beta-adrenergic Blockers, Vasodilators, and Angiotensin-converting Enzyme Inhibitors] and Surgeries [Angioplasty, Artificial Heart Valve Surgery, and Bypass Surgery]), Route of Administration (Injectable and Oral), and Distribution Channels (Online Pharmacies, Retail Pharmacies, and Hospital Pharmacies)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Daiichi Sankyo Co Ltd; Boehringer Ingelheim International GmbH; Pfizer Inc.; Merck KGaA; Bristol-Myers Squibb Co.; Bayer AG; Johnson & Johnson Services Inc.; Sanofi S.A.; Novartis International AG; and AstraZeneca plc.
|
Market Segment Insights
Blood tests segment to register considerable market share
Based on diagnosis, the market is segmented into echocardiogram, electrocardiogram, and blood tests. The blood test segment is further categorized into troponin and CK-MB. The blood tests segment is projected to register considerable market share in the coming years, owing to its low turnaround time and rapid results. Troponin test is considered as a standard method in diagnosis of myocardial infraction. The echocardiogram segment is expected to register substantial CAGR. Electrocardiogram is a test for diagnosis of heart attack and it is used to check heart rhythm and electrical activity.
Drugs segment to expand at a considerable CAGR
On the basis of treatments, the myocardial infarction market is segregated into drugs and surgeries. The drugs segment is further classified as angiotensin-receptor blockers, analgesics, thrombolytics, antiplatelet agents, glycoprotein IIb/IIIa inhibitors, antithrombotic agents, beta-adrenergic blockers, vasodilators, and angiotensin-converting enzyme inhibitors. The surgery segment is further categorized into angioplasty, artificial heart valve surgery, and bypass surgery. The drugs segment is projected to expand at a considerable CAGR during the forecast period, as it is a major preventive treatment and thwarts the formation of blood clots. The surgeries segment is anticipated to account for a major market share during the forecast period, as it is an efficient process and it lowers the risk of stroke.
Oral segment to hold a significant share of the market
Based on route of administration, the market is divided into injectable and oral. The oral segment is expected to hold a significant share of the market in the coming years, due to rising adoption of minimally invasive treatment. The injectable segment accounts for a significant market share, owing to the increasing demand for effective and fast drug delivery.
Hospital pharmacies segment to expand at a substantial CAGR
On the basis of distribution channels, the myocardial infarction market is segregated into online pharmacies, retail pharmacies, and hospital pharmacies. The hospital pharmacies segment is anticipated to expand at a substantial CAGR during the forecast period, owing to increasing cases of cardiovascular disease. The retail pharmacies segment is expected to hold a significant share of the market, due to high-quality customer service provided in retail pharmacies.
North America is anticipated to constitute a key market share
In terms of regions, the myocardial infarction market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to constitute a key share of the market during the forecast period, owing to increasing public initiatives and awareness programs on cardiovascular disease in the region. The market in Asia Pacific is anticipated to expand at a rapid pace during the forecast period, due to increasing research and development activities regarding myocardial infarction in the region.
Segments
The global myocardial infarction market has been segmented on the basis of
Diagnosis
- Echocardiogram
- Electrocardiogram
- Blood Tests
Treatments
- Drugs
- Angiotensin-receptor Blockers
- Analgesics
- Thrombolytics
- Antiplatelet Agents
- Glycoprotein IIb/IIIa Inhibitors
- Antithrombotic Agents
- Beta-adrenergic Blockers
- Vasodilators
- Angiotensin-converting Enzyme Inhibitors
- Surgeries
- Angioplasty
- Artificial Heart Valve Surgery
- Bypass Surgery
Route of Administration
Distribution Channels
- Online Pharmacies
- Retail Pharmacies
- Hospital Pharmacies
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Daiichi Sankyo Co Ltd
- Boehringer Ingelheim International GmbH
- Pfizer Inc.
- Merck KGaA
- Bristol-Myers Squibb Co.
- Bayer AG
- Johnson & Johnson Services Inc.
- Sanofi S.A.
- Novartis International AG
- AstraZeneca plc.
Competitive Landscape
Key players competing in the global myocardial infarction market are Daiichi Sankyo Co Ltd; Boehringer Ingelheim International GmbH; Pfizer Inc.; Merck KGaA; Bristol-Myers Squibb Co.; Bayer AG; Johnson & Johnson Services Inc.; Sanofi S.A.; Novartis International AG; and AstraZeneca plc.
Key players are developing innovative myocardial infraction treatment systems through research and organic growth strategies. These companies also adopt acquisitions and collaborations to boost their market share. On May 26, 2020, Boehringer Ingelheim and Eli Lilly and Company introduced an academic research collaboration with the Duke Clinical Research Institute. This collaboration proposes to investigate whether empagliflozin improves results in adults and prevents coronary heart failure with or without diabetes.
Request For Customization
Enquiry Before Buying
Speak With Analyst
